A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

NCT01558271 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of the medication LY2189265 in Japanese adults with type 2 diabetes to see how it affects their blood sugar levels over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 492 people

Who can join Ages 20+ · all sexes

Timeline Started 2012-03 · est. completion 2014-05

Where 14 sites · Japan

What this study is testing ClinicalTrials.gov NCT01558271 ↗

Description as written by the study sponsor.

The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 in participants with type 2 diabetes mellitus who are not taking oral antidiabetic medication.

Treatments tested

LY2189265 also known as Dulaglutide Drug
Placebo Drug
Liraglutide Drug

Main thing measured	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01558271 ↗